Nektar Therapeutics (NKTR) Cash from Operations (2010 - 2026)

Nektar Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 44298000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 9.69% year-over-year to 44298000.0; the TTM figure through Mar 2026 stood at 203756000.0 (down 15.2% YoY), while the FY2025 annual figure was 208511000.0, down 18.67% from the prior year.
• Cash from Operations was 44298000.0 for Q1 2026 at Nektar Therapeutics, up from 64959000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 37702000.0 in Q2 2024 to a low of 88424000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 54419470.59 across 5 years, with a median of 48761000.0 in 2025.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations soared 61.92% in 2022, then sank 40.64% in 2025.
• A 5-year view of Cash from Operations shows it stood at 57703000.0 in 2022, then grew by 18.47% to 47047000.0 in 2023, then increased by 1.83% to 46187000.0 in 2024, then tumbled by 40.64% to 64959000.0 in 2025, then jumped by 31.81% to 44298000.0 in 2026.
• The last three Cash from Operations figures came in at 44298000.0 (Q1 2026), 64959000.0 (Q4 2025), and 48761000.0 (Q3 2025), per Business Quant data.